Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

K. Papp; D. Thaçi; K. Reich; E. Riedl; R. G. Langley; J. G. Krueger; A. B. Gottlieb; H. Nakagawa; E. P. Bowman; A. Mehta; Q. Li; Y. Zhou; R. Shames

doi:10.1111/bjd.13932

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

K. Papp, D. Thaçi, K. Reich, E. Riedl, R. G. Langley, J. G. Krueger, A. B. Gottlieb, H. Nakagawa, E. P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

241 Citations (Scopus)

Original language	English
Pages (from-to)	930-939
Number of pages	10
Journal	British Journal of Dermatology
Volume	173
Issue number	4
DOIs	https://doi.org/10.1111/bjd.13932
Publication status	Published - Oct 2015

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.13932

Cite this

Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R. G., Krueger, J. G., Gottlieb, A. B., Nakagawa, H., Bowman, E. P., Mehta, A., Li, Q., Zhou, Y., & Shames, R. (2015). Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. British Journal of Dermatology, 173(4), 930-939. https://doi.org/10.1111/bjd.13932

Papp, K, Thaçi, D, Reich, K, Riedl, E, Langley, RG, Krueger, JG, Gottlieb, AB, Nakagawa, H, Bowman, EP, Mehta, A, Li, Q, Zhou, Y & Shames, R 2015, 'Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial', British Journal of Dermatology, vol. 173, no. 4, pp. 930-939. https://doi.org/10.1111/bjd.13932

@article{85a9cdcf4bf74d0e8426c96581ccc488,

title = "Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial",

author = "K. Papp and D. Tha{\c c}i and K. Reich and E. Riedl and Langley, {R. G.} and Krueger, {J. G.} and Gottlieb, {A. B.} and H. Nakagawa and Bowman, {E. P.} and A. Mehta and Q. Li and Y. Zhou and R. Shames",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2015",

month = oct,

doi = "10.1111/bjd.13932",

language = "English",

volume = "173",

pages = "930--939",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

AU - Papp, K.

AU - Thaçi, D.

AU - Reich, K.

AU - Riedl, E.

AU - Langley, R. G.

AU - Krueger, J. G.

AU - Gottlieb, A. B.

AU - Nakagawa, H.

AU - Bowman, E. P.

AU - Mehta, A.

AU - Li, Q.

AU - Zhou, Y.

AU - Shames, R.

PY - 2015/10

Y1 - 2015/10

UR - http://www.scopus.com/inward/record.url?scp=84945443119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945443119&partnerID=8YFLogxK

U2 - 10.1111/bjd.13932

DO - 10.1111/bjd.13932

M3 - Article

C2 - 26042589

AN - SCOPUS:84945443119

SN - 0007-0963

VL - 173

SP - 930

EP - 939

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this